top partner

for CFD

What happened

Shares of ImmunityBio (NASDAQ: IBRX) were up more than 30% for the week as of 10 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech‘s stock closed at $1.29 last week and then rose to as high as $1.785 on Tuesday. The move came after the company announced a stock sale and refinancing worth $470 million led by the company’s founder. ImmunityBio stock is still down more than 72% so far this year.

So what

ImmunityBio focuses on cell therapies and immunotherapies. The company said on Monday that Dr. Patrick Soon-Shiong, ImmunityBio’s founder, executive chairman, and chief scientific and medical officer, would contribute $200 million in financing in return for stock. In addition, the company restructured $270 million of debt with Nant Capital in return for ImmunityBio stock.

While the move certainly dilutes the value of shares, it also shows the confidence that Soon-Shiong had in the company’s potential as it awaits the potential Food and Drug Administration (FDA) approval of Anktiva plus Bacillus Calmette-Guérin immunotherapy (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer. Anktiva would be the company’s first FDA-approved therapy.

Now what

Soon-Shiong’s move represents a big bet on Anktiva — which is in two late-stage trials to treat bladder cancer — and the business as a whole. If Anktiva is approved, the move will pay off big for Soon-Shiong. The company has 13 programs in its pipeline, including six in phase 2 or later. Anktiva could be quite valuable to ImmunityBio as bladder cancer is expected to affect roughly 82,290 new people in the U.S. this year and is the fourth most common solid tumor in men and 12th most common in women, according to the American Cancer Society.

10 stocks we like better than ImmunityBio
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and ImmunityBio wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 11, 2023

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Read the full story: Read More“>

Blog powered by G6

Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.

For any inquiries, please contact [email protected]